TransCode Therapeutics, Inc. announces the appointment of Jack E. Stover to its Board of Directors, bringing decades of experience in life sciences companies.
Mr. Stover will join the Audit and Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.
His expertise spans drug development, diagnostics, specialty pharmaceuticals, and capital formation.
Extensive Leadership Experience
Jack E. Stover brings over three decades of executive leadership experience in public and private life sciences companies.
Strategic Expertise
Mr. Stover's strategic expertise and successes in leading transformative growth will benefit TransCode's RNA and immuno-oncology pipeline.
Chairman of Traws Pharma Inc.
Currently serving as Chairman of the Board of Traws Pharma Inc., a specialty pharmaceutical company focused on anti-virals and oncology.
Previous CEO Roles
Mr. Stover has held CEO positions at notable companies including NorthView Acquisition Corp., Interpace Biosciences, and Antares Pharma, Inc.
Vision for TransCode
Excited to join TransCode's Board and looks forward to advancing the mission of delivering a cancer-free future for patients.
- The addition of Jack E. Stover brings a wealth of experience in areas crucial to TransCode's growth, such as drug development, diagnostics, and financial expertise.
- His history of leading successful mergers and acquisitions in the pharmaceutical industry indicates potential strategic moves for TransCode.
- Stover's appointment signals a new phase of development for TransCode, with a focus on advancing RNA and immuno-oncology solutions for high-risk cancer treatment.
Jack E. Stover's appointment to the Board of Directors at TransCode Therapeutics marks a significant milestone for the company, aligning with their mission to advance innovative cancer treatments. His vast experience sets a strong foundation for future growth and strategic initiatives within the company.